AstraZeneca’s Tagrisso Plus Chemotherapy Receives the EC’s Approval to Treat EGFR-Mutated Advanced Lung Cancer
Shots:
- Approval was based on P-III (FLAURA2) study of Tagrisso (80mg, oral, QD) + CT [pemetrexed (500mg/m^2) + cisplatin (75mg/m^2) or carboplatin (AUC5), Q3W] followed by Tagrisso with pemetrexed maintenance (Q3W) in locally advanced (Stage IIIB-IIIC) or metastatic (Stage IV) EGFRm NSCLC patients (n=557)
- Study depicted 38% PFS & 25.5mos. vs 16.7mos. mPFS as per investigator evaluation; similar PFS with mPFS of 29.4mos. vs 19.9mos. was observed as per BICR. OS data was immature (41% maturity), though a trend was observed, its evaluation is underway
- Prespecified exploratory analysis showed 42% reduced CNS disease progression or death risk with 74% vs 54% of patients not having it after 2yrs. follow-up
Ref: Astrazeneca | Image: Astrazeneca
Related News:- AstraZeneca’s Tagrisso Plus Chemotherapy Receives NMPA’s Approval to Treat EGFR-Mutated Advanced Lung Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
